# Phase I Oral mTOR Inhibitor RAD001 in Combo w/ Capecitabine for Metastatic Breast

> **NCT00473005** · PHASE1 · TERMINATED · sponsor: **Stanford University** · enrollment: 18 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** RAD001

## Key facts

- **NCT ID:** NCT00473005
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-08
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Principal Investigator (Dr. Guardino) left Stanford
- **Last updated:** 2012-05-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00473005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00473005, "Phase I Oral mTOR Inhibitor RAD001 in Combo w/ Capecitabine for Metastatic Breast". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00473005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*